Design and Rationale of the Quazar Lower-Risk Mds (Aza-Mds-003) Trial: a Randomized Phase 3 Study of Cc-486 (Oral Azacitidine) plus Best Supportive Care Vs Placebo plus Best Supportive Care in Patients with Ipss Lower-Risk Myelodysplastic Syndromes and Poor Prognosis Due to Red Blood Cell Transfusion–Dependent Anemia and Thrombocytopenia